NEW YORK (GenomeWeb News) – Response Biomedical today reported that product sales for the first quarter rose 50 percent year over year on the strength of its cardiovascular tests.

The Vancouver, British Columbia-based firm recorded product sales of C$3 million (US$3 million) for the three months ended March 31, up from $2 million a year ago, as cardiovascular sales increased 80 percent year over year to $2.7 million from $1.5 million. Improved performance in China was the primary driver of growth in the cardiovascular business, Response Biomedical said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits sequencing newborns is underway.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.